Physician profile
Leslie Mack
NPI 1508172552
$7,133.68
in general payments reported to CMS, 2019-2025
42 companies · $1,286 in 2025
The $1,286 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,478 · 2022: $1,448 · 2023: $1,298 · 2024: $1,624 · 2025: $1,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,207.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $815.48 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $787.53 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Medtronic, INC. | $668.64 | 2021-2024 | Minimed 780g |
| Corcept Therapeutics | $611.69 | 2022-2025 | Korlym |
| Abbvie INC. | $601.97 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $595.96 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $555.87 | 2021-2025 | Tradjenta, Jardiance, Synjardy |
| Insulet Corporation | $342.42 | 2022-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $191.06 | 2021-2025 | Gvoke Hypopen |
| Dexcom, INC. | $177.84 | 2023-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Recordati_rare_diseases_inc. | $162.15 | 2023-2025 | Isturisa, Signifor Lar |
| Cequr Corporation | $159.80 | 2024-2025 | Cequr Simplicity |
| Abbott Laboratories | $151.82 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $140.74 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $133.00 | 2021-2025 | Unithroid |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $113.61 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $86.83 | 2022-2024 | Senza |
| Amgen INC. | $80.53 | 2021-2024 | Tepezza |
| Ibsa Pharma INC. | $79.96 | 2023-2025 | Tirosint, Licart, Licart |
| Ascensia Diabetes Care US INC. | $77.45 | 2024 | |
| Ascendis Pharma Endocrinology INC | $56.20 | 2025 | Yorvipath |
| Amarin Pharma, INC. | $50.00 | 2021 | |
| Chiesi USA, INC. | $49.34 | 2025 | Mycapssa |
| Radius Health, INC. | $48.26 | 2023-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $47.32 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $41.41 | 2021-2022 | |
| Esperion Therapeutics, INC. | $34.24 | 2021 | |
| Merck Sharp & Dohme LLC | $30.97 | 2022 | |
| Sequel Med Tech, LLC | $23.88 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $23.77 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $22.27 | 2024 | Xyosted |
| Beta Bionics, INC. | $21.08 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ultragenyx Pharmaceutical INC. | $18.50 | 2022 | |
| Globus Medical, INC. | $17.39 | 2025 | Senza |
| Astellas Pharma US INC | $16.79 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.70 | 2022 | |
| Pfizer INC. | $14.75 | 2022 | |
| Sumitomo Pharma America, INC. | $13.86 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $13.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.53 | 2021 | |
| Amryt Pharma Holdings Ltd | $13.33 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.94 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.